Cadrenal Therapeutics, INC Form 4 insider transactions

Cadrenal Therapeutics' Chief Financial Officer, Matthew Szot, was granted 50,000 stock options on January 23, 2025.

Cadrenal Therapeutics CEO and Chairman, Quang X. Pham, was granted 65,000 stock options on January 23, 2025.

Robert Lisicki, a director at Cadrenal Therapeutics, acquired 20,000 stock options on January 23, 2025.

CEO Quang Pham of Cadrenal Therapeutics donates 50,000 shares of common stock to a non-profit organization on April 10, 2024.

Jeffrey Scott Cole, Chief Operating Officer of Cadrenal Therapeutics, Inc., acquired options to purchase 150,000 shares of common stock on April 2, 2024.